Avelox advantage over levofloxacin in community-acquired infection

27 April 2008

A therapy's overall clinical efficacy (defined as cure or improvement of symptoms) is the attribute that most influences primary care physicians' prescribing decisions for community-acquired pneumonia, according to Decision Resources, a leading research and advisory firm focusing on pharmaceutical and health care issues.

Clinical data and expert opinion show that Bayer/Schering-Plough/Shionogi's Avelox (moxifloxacin) is similar in overall clinical efficacy to the market leader levofloxacin, marketed by USA-based Johnson & Johnson as Levaquin, France's Sanofi-Aventis as Tavanic and Daiichi Sankyo as Cravit. However, Avelox' Japan's advantages in bacteriological efficacy, spectrum of activity, and activity against key antibiotic-resistant pathogens earn the agent gold standard status for community acquired pneumonia.

The new report, entitled Community-Acquired Pneumonia: In a Crowded Generics-Dominated Market, Room for New Agents Still Exists, finds that, through 2016, there are no therapies in development that will displace Avelox as the clinical gold standard for the treatment of community-acquired pneumonia. Although levofloxacin is superior to Avelox in the areas of safety and delivery - offering a lower incidence of dermatological reactions and a five-day course of treatment - the latter outperforms levofloxacin on efficacy measures such as bacteriological eradication and activity against penicillin-resistant Streptococcus pneumoniae and methicillin-resistant Staphylococcus aureus.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight